Merus (MRUS) Competitors $55.34 -0.03 (-0.05%) As of 11:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. ITCI, GMAB, RDY, MRNA, ASND, VTRS, QGEN, ROIV, RVMD, and BPMCShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Merus vs. Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Ascendis Pharma A/S Viatris Qiagen Roivant Sciences Revolution Medicines Blueprint Medicines Merus (NASDAQ:MRUS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment. Do analysts rate MRUS or ITCI? Merus currently has a consensus price target of $86.00, indicating a potential upside of 55.32%. Intra-Cellular Therapies has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given Merus' stronger consensus rating and higher probable upside, equities analysts plainly believe Merus is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.13Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Do insiders & institutionals have more ownership in MRUS or ITCI? 96.1% of Merus shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 4.6% of Merus shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in MRUS or ITCI? Intra-Cellular Therapies received 155 more outperform votes than Merus when rated by MarketBeat users. However, 67.96% of users gave Merus an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformMerusOutperform Votes36767.96% Underperform Votes17332.04% Intra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% Does the media prefer MRUS or ITCI? In the previous week, Merus had 31 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 31 mentions for Merus and 0 mentions for Intra-Cellular Therapies. Merus' average media sentiment score of 0.70 beat Intra-Cellular Therapies' score of 0.00 indicating that Merus is being referred to more favorably in the media. Company Overall Sentiment Merus Positive Intra-Cellular Therapies Neutral Is MRUS or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Merus' net margin of -680.61%. Intra-Cellular Therapies' return on equity of -9.93% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Merus-680.61% -38.89% -31.16% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has more volatility and risk, MRUS or ITCI? Merus has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Which has stronger valuation & earnings, MRUS or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Merus. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$54.73M70.02-$154.94M-$4.08-13.57Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 SummaryMerus beats Intra-Cellular Therapies on 12 of the 19 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.83B$6.53B$5.39B$8.47BDividend YieldN/A2.64%5.28%4.17%P/E Ratio-14.028.7326.9919.79Price / Sales70.02257.87412.17137.59Price / CashN/A65.8538.2534.64Price / Book8.976.466.844.53Net Income-$154.94M$143.21M$3.22B$247.85M7 Day Performance33.10%4.52%2.41%2.41%1 Month Performance22.91%4.27%10.70%10.70%1 Year Performance2.54%1.10%21.06%10.73% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.8529 of 5 stars$55.34-0.1%$86.00+55.4%+2.5%$3.81B$54.73M-13.9537ITCIIntra-Cellular Therapies0.6723 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.4211 of 5 stars$20.81-1.0%$39.17+88.2%-23.8%$13.34B$3.12B11.961,660Positive NewsRDYDr. Reddy's Laboratories2.0539 of 5 stars$14.38+0.7%$17.00+18.2%+4.5%$12.00B$325.54B22.9024,800News CoveragePositive NewsMRNAModerna4.4932 of 5 stars$26.26-1.7%$53.58+104.0%-81.8%$10.16B$3.14B-2.833,900Trending NewsGap DownASNDAscendis Pharma A/S3.409 of 5 stars$162.00+1.2%$216.07+33.4%+23.4%$9.88B$368.70M-22.82640Positive NewsVTRSViatris2.3012 of 5 stars$8.29-2.5%$10.50+26.7%-14.4%$9.73B$14.33B-11.2037,000Trending NewsQGENQiagen3.2633 of 5 stars$42.07-0.6%$48.42+15.1%+8.5%$9.35B$2.00B117.146,030Positive NewsShort Interest ↑Analyst RevisionROIVRoivant Sciences2.2772 of 5 stars$10.87-0.6%$17.50+61.0%+5.3%$7.76B$122.59M-72.46860Trending NewsEarnings ReportAnalyst ForecastRVMDRevolution Medicines4.2927 of 5 stars$39.77+2.5%$67.08+68.7%+3.6%$7.41B$742,000.00-11.08250Positive NewsBPMCBlueprint Medicines1.8336 of 5 stars$101.50+1.2%$126.56+24.7%+2.5%$6.56B$562.12M-93.98640Positive NewsInsider Trade Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Ascendis Pharma A/S Competitors Viatris Competitors Qiagen Competitors Roivant Sciences Competitors Revolution Medicines Competitors Blueprint Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRUS Stock Free MRUS Stock Alerts